Unfortunately, preclinical and clinical evidence has shown that not all patients with BRCA-mutated tumors respond to PARP inhibitors [18], and PARP inhibitors are also effective for breast cancer cells lacking BRCA mutations [21, 22]. This evidence concerns the gene PARP1 and breast carcinoma.